AbCellera Biologics Inc (NAS:ABCL)
$ 2.995 0.045 (1.53%) Market Cap: 871.33 Mil Enterprise Value: 299.59 Mil PE Ratio: 0 PB Ratio: 0.81 GF Score: 66/100

Q4 2022 Abcellera Biologics Inc Earnings Call Transcript

Feb 21, 2023 / 10:00PM GMT
Release Date Price: $8.89 (-7.30%)
Operator

Good afternoon, and welcome to AbCellera Full Year 2022 Business Update Conference Call. My name is Daniel, and I will facilitate the audio portion of today's interactive broadcast. (Operator Instructions)

At this time, I would like to turn the call over to Tryn Stimart, AbCellera's Chief Legal and Compliance Officer. Please proceed.

Tryn T. Stimart
AbCellera Biologics Inc. - Chief Legal Officer, Chief Compliance Officer & Corporate Secretary

Thank you. Good afternoon, and welcome to AbCellera's full year and fourth quarter 2022 business update. We are pleased to have you with us today as we discussed the results announced in our press release issued after the market close today, which you can find on our Investor Relations website.

With me on the call today are Dr. Carl Hansen, AbCellera's Chief Executive Officer and President; and Andrew Booth, AbCellera's Chief Financial Officer. The webcast portion of this call contains a slide presentation that we will refer to during the call. If you are following along on the phone and wish to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot